Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Who cites it

105 citing papers in PubMed, 199 citations in OpenAlex.

1. A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.Blood · 2026
   Trial
2. Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.Blood advances · 2024
   Trial
3. Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
   Trial
4. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.Blood · 2021
   Trial
5. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
   Trial
6. BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.Blood · 2021
   Trial
7. Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.Blood · 2021
   Trial
8. Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
   Trial
9. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.Blood · 2021
   Trial
10. A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.American journal of hematology · 2020
    Trial
11. Ibrutinib for Chronic Lymphocytic Leukemia withThe New England journal of medicine · 2020
    Trial
12. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.American journal of hematology · 2019
    Trial
13. Hypertension and incident cardiovascular events following ibrutinib initiation.Blood · 2019
    Trial
14. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Trial
15. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.The Lancet. Haematology · 2019
    Trial
16. Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.Blood · 2019
    Trial
17. Ibrutinib and Venetoclax for First-Line Treatment of CLL.The New England journal of medicine · 2019
    Trial
18. Understanding and Overcoming Osteosarcoma Heterogeneity.Biomolecules · 2026
    Review
19. Cardiovascular Toxicity of BTKi in Chronic B-Cell Malignancies.Reviews in cardiovascular medicine · 2026
    Review
20. Sudden death and asymptomatic arrhythmia in chronic lymphocytic leukemia patients treated with ibrutinib.Heart rhythm · 2026
    Article

45 more citing papers are in PubMed but not listed here.

Corrections and comments

• Commented on by
  Five years of ibrutinib in CLL.2018

Authors and funding

24 authors at 9 institutions in 3 countries.

Funding

Abstract

Indexed as